Treatment of rhegmatogenous retinal detachment: from the past to the future
Rhegmatogenous retinal detachment (RRD) is a severe disorder that can potentially lead to blindness. The traction developing in pathological attachment of the vitreous to retinal degeneration areas and in posterior hyaloid detachment leads to formation of retinal breaks and subsequent retinal detach...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Ukrainian Society of Ophthalmologists
2020-02-01
|
Series: | Journal of Ophthalmology |
Subjects: | |
Online Access: | https://www.ozhurnal.com/en/archive/2020/1/8-fulltext |
_version_ | 1797387593699033088 |
---|---|
author | M. Iu. Krongauz I.O. Nasinnyk N.V. Pasyechnikova |
author_facet | M. Iu. Krongauz I.O. Nasinnyk N.V. Pasyechnikova |
author_sort | M. Iu. Krongauz |
collection | DOAJ |
description | Rhegmatogenous retinal detachment (RRD) is a severe disorder that can potentially lead to blindness. The traction developing in pathological attachment of the vitreous to retinal degeneration areas and in posterior hyaloid detachment leads to formation of retinal breaks and subsequent retinal detachment. The approach to treatment of RRD has changed with years from cautery (J. Gonin, 1920) to modern vitrectomy (R. Machemer, 1973). Current advances in vitrectomy are related mostly to the three major fields: development of advanced vitrectomy tools, novel operative techniques and tamponade agents. The tamponade agents used in vitrectomy have specific advantages and disadvantages. Therefore, new solutions are being sought to minimize harmful effects of tamponade agents on ocular tissues, which would make the process of rehabilitation more comfortable for patients. In recent decades, the potential for using hydrogels as a substitute to the vitreous removed during vitrectomy has been actively explored (Widder, 1960, Balazs, 1972, Malson, 1985). The first commercially available biomedical sodium hyaluronate product for use in eye surgery, Healon, was developed by Balazs. Although Healon was developed as a vitreous substitute, it has been successfully used also in cataract surgery, and truly initiated the age of viscosurgery. The research on the potential for using hydrogels as a visual substitute is underway. |
first_indexed | 2024-03-08T22:28:21Z |
format | Article |
id | doaj.art-722b2431cf984edea9de975054e65f0c |
institution | Directory Open Access Journal |
issn | 2412-8740 |
language | English |
last_indexed | 2024-03-08T22:28:21Z |
publishDate | 2020-02-01 |
publisher | Ukrainian Society of Ophthalmologists |
record_format | Article |
series | Journal of Ophthalmology |
spelling | doaj.art-722b2431cf984edea9de975054e65f0c2023-12-18T09:07:59ZengUkrainian Society of OphthalmologistsJournal of Ophthalmology2412-87402020-02-011404810.31288/oftalmolzh202014048Treatment of rhegmatogenous retinal detachment: from the past to the futureM. Iu. Krongauz0I.O. Nasinnyk1N.V. Pasyechnikova2Filatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Science of UkraineFilatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Science of UkraineFilatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Science of UkraineRhegmatogenous retinal detachment (RRD) is a severe disorder that can potentially lead to blindness. The traction developing in pathological attachment of the vitreous to retinal degeneration areas and in posterior hyaloid detachment leads to formation of retinal breaks and subsequent retinal detachment. The approach to treatment of RRD has changed with years from cautery (J. Gonin, 1920) to modern vitrectomy (R. Machemer, 1973). Current advances in vitrectomy are related mostly to the three major fields: development of advanced vitrectomy tools, novel operative techniques and tamponade agents. The tamponade agents used in vitrectomy have specific advantages and disadvantages. Therefore, new solutions are being sought to minimize harmful effects of tamponade agents on ocular tissues, which would make the process of rehabilitation more comfortable for patients. In recent decades, the potential for using hydrogels as a substitute to the vitreous removed during vitrectomy has been actively explored (Widder, 1960, Balazs, 1972, Malson, 1985). The first commercially available biomedical sodium hyaluronate product for use in eye surgery, Healon, was developed by Balazs. Although Healon was developed as a vitreous substitute, it has been successfully used also in cataract surgery, and truly initiated the age of viscosurgery. The research on the potential for using hydrogels as a visual substitute is underway. https://www.ozhurnal.com/en/archive/2020/1/8-fulltextvitrectomysilicone oilgas tamponaderhegmatogenous retinal detachmenthydrogelviscosurgery |
spellingShingle | M. Iu. Krongauz I.O. Nasinnyk N.V. Pasyechnikova Treatment of rhegmatogenous retinal detachment: from the past to the future Journal of Ophthalmology vitrectomy silicone oil gas tamponade rhegmatogenous retinal detachment hydrogel viscosurgery |
title | Treatment of rhegmatogenous retinal detachment: from the past to the future |
title_full | Treatment of rhegmatogenous retinal detachment: from the past to the future |
title_fullStr | Treatment of rhegmatogenous retinal detachment: from the past to the future |
title_full_unstemmed | Treatment of rhegmatogenous retinal detachment: from the past to the future |
title_short | Treatment of rhegmatogenous retinal detachment: from the past to the future |
title_sort | treatment of rhegmatogenous retinal detachment from the past to the future |
topic | vitrectomy silicone oil gas tamponade rhegmatogenous retinal detachment hydrogel viscosurgery |
url | https://www.ozhurnal.com/en/archive/2020/1/8-fulltext |
work_keys_str_mv | AT miukrongauz treatmentofrhegmatogenousretinaldetachmentfromthepasttothefuture AT ionasinnyk treatmentofrhegmatogenousretinaldetachmentfromthepasttothefuture AT nvpasyechnikova treatmentofrhegmatogenousretinaldetachmentfromthepasttothefuture |